| Detailed information |
|---|
| CancerLivER ID | 2580 |
| Biomarker | Dystrophin, Homolog to tubulin beta chain, Zinc finger protein 337, Friedreich ataxia region gene X123, Fibronectin (Alt. Splice 1), Zinc finger protein 9, Metallothionein IV, Poly(rC) binding protein 3, KIAA0426 gene product, Hypothetical protein FLJ13910, RAN binding protein 2 like 1, S100 calcium |
| Biomarker Name/Symbol (given in Publication) | Dystrophin, Homolog to tubulin beta chain, Zinc finger protein 337, Friedreich ataxia region gene X123, Fibronectin (Alt. Splice 1), Zinc finger protein 9, Metallothionein IV, Poly(rC) binding protein 3, KIAA0426 gene product, Hypothetical protein FLJ13910, RAN binding protein 2-like 1, S100 calcium binding protein A2, Apolipoprotein B, Sulfotransferase family, cytosolic, 2B, member 1, Zinc finger protein 103 homolog (mouse), Fibronectin 1, Zinc finger protein-like 1, EST |
| Biomolecule | RNAs |
| Subject | Human |
| Degree of Validity | Potential prognostic marker for grade progression of HCC and associated invasion and with metastsis of HCC; but not validated on indepedent dataset |
| Experimental Condition | non-tumorous livers L1 (with HCV infection) v/s and L0 (without HCV infection) ; associated with invasion or metastsis |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Downregulated in L1 than L0 (with fisher ratio more than 9.74) |
| Level of significance | P = 0.001 |
| Source | Tissue |
| PMID | 15710396 |
| Type of Biomarker | Prognostic |
| Pathway | induces apoptosis of some types of cancer cells, and IGFBP4 acts as an inhibitor of IGF-in- duced cell proliferation. |
| Cohort | 76 HCC samples : 50 were sero- positive for HCV antibody (HCVAb) and seronegative for hepatitis B virus surface antigen (HBsAg) and among 50 (7G1 (well differentiated, 35 G2 (moderately differentiated) and 10 G3 (poorly differentiated); 26 were seronegative for HCVAb |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | Hepatocellular carcinoma (HCC) samples with positive hepatitis C virus (HCV) serology (well (G1), moderately (G2), and poorly (G3) differentiated tumors) with and without HCV infection. |
| Year of Publication | 2005 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |